| abstract |
The invention relates to compounds of general formula: in which R1 denotes hydrogen alkyl or hydroxy-alkyl low, R 2 denotes furyl, thenyl, pyridyl or phenyl, optionally replaced by one to 3 alternatives, selected from alkyl low, alkoxy low, halogen, Ciano CF 3 or –N (R4) 2, R3 denotes nephthalate or phenyl, optionally substituted by one to 3 alternatives, excluding low alkyl, alkoxy low, halogen, acetyl, cyano, hydroxy-alkyl, CH 2 4.Yel, alkyl, oxy-alkyl, alkyl, N (R4) 2, or CF3 R4 denoting each unit, hydrogen or alkyl, the equivalent of RS-2-phenyl-1- (toluene-4-sulfonyl) –Pyrol Religion or RS -1- (toluene -4- sulfonyl) -2 P Tolal- pyrrolidine as well as their salts acceptable pharmacologically. " The compounds described above are antagonists or metabolites of glutamate receptor metabolites and are therefore useful in the treatment of corresponding SCN disorders. |